Compare SPCB & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | BSEM |
|---|---|---|
| Founded | 1988 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.2M | 59.6M |
| IPO Year | 2004 | 2026 |
| Metric | SPCB | BSEM |
|---|---|---|
| Price | $10.11 | $3.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 111.8K | ★ 114.1K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $2.25 |
| 52 Week High | $13.57 | $4.66 |
| Indicator | SPCB | BSEM |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 46.76 |
| Support Level | $7.89 | $2.25 |
| Resistance Level | $10.78 | $4.02 |
| Average True Range (ATR) | 0.47 | 0.33 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 15.03 | 70.01 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.